| A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203) (NCT02318277) | Incyte Corporation | 2015-01-05 |
| Phase I Study of Intravenous Artesunate for Solid Tumors (NCT02353026) | Georgetown University | 2015-01-01 |
| A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors (NCT02324257) | Hoffmann-La Roche | 2014-12-30 |
| Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials (NCT02315599) | National Cancer Institute (NCI) | 2014-12-23 |
| A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors (NCT02304393) | Hoffmann-La Roche | 2014-12-12 |
| Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors (NCT02533674) | PharmaMar | 2014-12-12 |
| INVAC-1 Anti-Cancer hTERT DNA Immunotherapy (NCT02301754) | Invectys | 2014-11-01 |
| Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors (NCT02307240) | Curis, Inc. | 2014-11-01 |
| Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations (NCT02304809) | UNICANCER | 2014-10-13 |
| Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors (NCT02262455) | Santa Maria Biotherapeutics | 2014-10-01 |
| First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients (NCT02277717) | Byondis B.V. | 2014-10-01 |
| An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies (NCT02265510) | Incyte Corporation | 2014-09-10 |
| A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b (NCT02279433) | Nuvation Bio Inc. | 2014-09-01 |
| Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors (NCT01940601) | Teva Branded Pharmaceutical Products R&D, Inc. | 2014-09-01 |
| ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin (NCT02435927) | National Cancer Centre, Singapore | 2014-08-01 |
| Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments (NCT01994031) | Nanjing Luye Sike Pharmaceutical Co., Ltd. | 2014-08-01 |
| This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas (NCT02171260) | Eisai Inc. | 2014-07-31 |
| Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers (NCT02178722) | Incyte Corporation | 2014-07-17 |
| Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection (NCT02095951) | Children's Hospital of Michigan | 2014-06-01 |
| Phase I Study of Oral DFP-11207 in Solid Tumors (NCT02171221) | Delta-Fly Pharma, Inc. | 2014-06-01 |
| A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) (NCT02130466) | Merck Sharp & Dohme LLC | 2014-05-29 |
| An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective (NCT02116803) | Novartis Pharmaceuticals | 2014-05-28 |
| Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors (NCT02071537) | University of Cincinnati | 2014-05-13 |
| Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer (NCT02240238) | NanoCarrier Co., Ltd. | 2014-05-01 |
| Safety Study of EF-022 ( Modified Vitamin D Binding Protein Macrophage Activator) in Subjects With Advanced Solid Tumors (NCT02052492) | Efranat Ltd. | 2014-05-01 |
| My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (NCT02091141) | Genentech, Inc. | 2014-04-14 |
| ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors (NCT02100007) | MEI Pharma, Inc. | 2014-04-01 |
| Investigator Initiated Phase 1 Study of TBI-1201 (NCT02096614) | Mie University | 2014-04-01 |
| Prospective Observational Study to Investigate the Added Value of the Health Related Quality of Life and Patient Reported Symptoms in the Identification of the Recommended Phase II Dose in Phase I Trials of Molecularly Targeted Therapies. (NCT02857699) | Institut Curie | 2014-04-01 |
| Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma (NCT02110563) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2014-04-01 |
| To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects (NCT02063230) | AstraZeneca | 2014-03-01 |
| Whey Protein Supplementation in Cancer Patients (NCT02065726) | Fondazione IRCCS Policlinico San Matteo di Pavia | 2014-02-25 |
| Phase I Study of KPT330 in Asian Patients (NCT02078349) | National University Hospital, Singapore | 2014-02-01 |
| Phase I Study of Chiauranib in Patients With Advanced Solid Tumors (NCT02122809) | Chipscreen Biosciences, Ltd. | 2014-02-01 |
| Study of Eribulin in Children With Cancer to Determine Safety (NCT02082626) | University of Oklahoma | 2014-02-01 |
| Study of the Glutaminase Inhibitor CB-839 in Solid Tumors (NCT02071862) | Calithera Biosciences, Inc | 2014-02-01 |
| Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) in Treatment Failure Solid Tumors (NCT02120118) | Shin Kong Wu Ho-Su Memorial Hospital | 2014-02-01 |
| PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors (NCT02022982) | Dana-Farber Cancer Institute | 2014-01-01 |
| CPCT-05 Biopsy Protocol Patient Selection (NCT01904916) | P.O. Witteveen | 2014-01-01 |
| Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors (NCT01988896) | Hoffmann-La Roche | 2013-12-27 |
| Phase II Clinical Trial of Uncaria Tomentosa (Cat´s Claw) in Patients With Advanced Solid Tumors (NCT02045719) | Faculdade de Medicina do ABC | 2013-12-01 |
| A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors (NCT02033551) | AbbVie | 2013-12-01 |
| Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors (NCT02610361) | BeiGene | 2013-11-20 |
| A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (NCT02009449) | Eli Lilly and Company | 2013-11-15 |
| An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors (NCT02038673) | Astellas Pharma Inc | 2013-11-05 |
| A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors (NCT02020226) | Threshold Pharmaceuticals | 2013-11-01 |
| Japanese Phase 1 Trial of Sym004 in Solid Tumors (NCT01955473) | Merck KGaA, Darmstadt, Germany | 2013-10-31 |
| Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment (NCT01949545) | Amgen | 2013-10-01 |
| Phase 1 Study of DS-8895a in Subjects With Advanced Solid Tumors (NCT02004717) | Daiichi Sankyo Co., Ltd. | 2013-10-01 |
| Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors (NCT01999738) | Endocyte | 2013-10-01 |
| Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN) (NCT01943461) | Merck KGaA, Darmstadt, Germany | 2013-09-02 |
| A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC (NCT01957007) | OncoMed Pharmaceuticals, Inc. | 2013-09-01 |
| Phase 1 Study of OTS167 in Patients With Solid Tumors (NCT01910545) | OncoTherapy Science, Inc. | 2013-08-23 |
| Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1 (NCT02034981) | UNICANCER | 2013-08-01 |
| A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm (NCT01905228) | Incuron | 2013-07-01 |
| To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors (NCT01922752) | Teva Branded Pharmaceutical Products R&D, Inc. | 2013-07-01 |
| An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate (NCT01844869) | Teva Branded Pharmaceutical Products R&D, Inc. | 2013-07-01 |
| Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib (NCT01844583) | Millennium Pharmaceuticals, Inc. | 2013-06-25 |
| NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors (NCT01875601) | National Cancer Institute (NCI) | 2013-06-11 |
| Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors (NCT01877811) | Hoffmann-La Roche | 2013-06-01 |
| Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors (NCT01858883) | Incyte Corporation | 2013-06-01 |
| Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287) (NCT01957280) | Daiichi Sankyo | 2013-06-01 |
| MEtoclopramide, DExamethasone or Axoli to Prevent or Delay Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy (NCT02135510) | Amsterdam UMC, location VUmc | 2013-06-01 |
| Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors (NCT01803503) | National University Hospital, Singapore | 2013-05-01 |
| Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis (NCT02213822) | Rhode Island Hospital | 2013-05-01 |
| A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors (NCT01832506) | Merck KGaA, Darmstadt, Germany | 2013-04-30 |
| Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies (NCT01930292) | Debiopharm International SA | 2013-04-01 |
| An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors (NCT01822756) | Incyte Corporation | 2013-04-01 |
| Phase 1 Study of ONT-10 in Patients With Solid Tumors (NCT01556789) | Cascadian Therapeutics Inc. | 2013-03-01 |
| Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) (NCT01772004) | EMD Serono Research & Development Institute, Inc. | 2013-01-31 |
| Safety and Efficacy of Repeated Infusion of CELYVIR in Children and Adults With Metastatic and Refractory Tumors. (NCT01844661) | Hospital Infantil Universitario Niño Jesús, Madrid, Spain | 2013-01-01 |
| Dexamethasone Dyspnea Study (NCT01670097) | M.D. Anderson Cancer Center | 2013-01-01 |
| Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas (NCT01490047) | Ludwig Institute for Cancer Research | 2013-01-01 |
| AZD1775 for Advanced Solid Tumors (NCT01748825) | National Cancer Institute (NCI) | 2012-12-19 |
| An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors (NCT01945710) | Eisai Limited | 2012-12-11 |
| Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas (NCT01799083) | Han weidong | 2012-12-01 |
| MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment (NCT01770353) | Ipsen | 2012-11-01 |
| Phase 1b Maintenance Therapy Study of ONT-10 in Patients With Solid Tumors (NCT01978964) | Cascadian Therapeutics Inc. | 2012-11-01 |
| Pharmacokinetics Study of Nimotuzumab in Patients With Solid Tumors (NCT02395068) | Biotech Pharmaceutical Co., Ltd. | 2012-11-01 |
| A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors (NCT01725555) | Axelar AB | 2012-10-01 |
| A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors (NCT01664000) | Cellceutix Corporation | 2012-10-01 |
| A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas (NCT02048488) | Tesaro, Inc. | 2012-10-01 |
| A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI (NCT01634555) | Eli Lilly and Company | 2012-10-01 |
| Metformin in Children With Relapsed or Refractory Solid Tumors (NCT01528046) | H. Lee Moffitt Cancer Center and Research Institute | 2012-09-24 |
| A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors (NCT01624467) | Eli Lilly and Company | 2012-08-01 |
| Effect of Tivantinib on the QTC Interval in Cancer Subjects (NCT01699061) | Daiichi Sankyo | 2012-07-01 |
| BIBF 1120 and RAD001 in Solid Tumors - Phase I (NCT01349296) | University of Cologne | 2012-07-01 |
| A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer (NCT01711034) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2012-06-01 |
| A Study of LY2875358 in Japanese Participants With Advanced Cancer (NCT01602289) | Eli Lilly and Company | 2012-06-01 |
| Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial (NCT01593228) | Sanofi | 2012-05-01 |
| Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors (NCT01544322) | MEI Pharma, Inc. | 2012-05-01 |
| Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors (NCT01525602) | Daiichi Sankyo | 2012-05-01 |
| A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors (NCT01603979) | AVEO Pharmaceuticals, Inc. | 2012-05-01 |
| Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors (NCT01548924) | Centro Nacional de Investigaciones Oncologicas CARLOS III | 2012-04-01 |
| A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors (NCT01577745) | MedImmune LLC | 2012-04-01 |
| Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma (NCT01568632) | National Cancer Institute (NCI) | 2012-03-01 |
| Erlotinib in Combination With Pralatrexate in Advanced Malignancies (NCT01532011) | M.D. Anderson Cancer Center | 2012-03-01 |
| Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors (NCT01324479) | Novartis Pharmaceuticals | 2012-02-29 |
| Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1) (NCT01431547) | Merck Sharp & Dohme LLC | 2012-02-01 |
| Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer (NCT01505153) | Gradalis, Inc. | 2012-02-01 |